

Publication list Marie-Luise Berres, MD PhD (US equivalence)

Original articles:

Henkel, C., Roderfeld, M., Weiskirchen, R., **Berres, M. L.**, Hillebrandt, S., Lammert, F., Meyer, H. E., Stuhler, K., Graf, J., and Roeb, E. Changes of the hepatic proteome in murine models for toxically induced fibrogenesis and sclerosing cholangitis. **Proteomics**. 2006;6(24):6538-48, **IF 4.132**

Roderfeld, M., Weiskirchen, R., Wagner, S., **Berres, M. L.**, Henkel, C., Grotzinger, J., Gressner, A. M., Matern, S., and Roeb, E. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. **FASEB J**. 2006;20(3):444-54, **IF 5.704**

Wasmuth, H. E., Moreno Zaldivar, M., **Berres, M. L.**, Werth, A., Scholten, D., Hillebrandt, S., Tacke, F., Schmitz, P., Dahl, E., Wiederholt, T., Hellerbrand, C., Berg, T., Weiskirchen, R., Trautwein, C., Lammert, F. The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. **J Hepatol**. 2008; 48(2):208-15, **IF 10.401**

Berres, M.L., Schnyder, B., Yagmur, E., Inglis, B., Tischendorf, J.J.W., Koch, A., Winograd, R., Trautwein, C., and Wasmuth, H.E. Longitudinal monocyte human leukocyte antigen-DR expression is a prognostic marker in critically ill patients with decompensated liver cirrhosis. **Liver Int**. 2009; 29(4):536-43, **IF 3.870**

Wiederholt, T., von Westernhagen, M., Zaldivar, M. M., **Berres M.L.**, Schmitz, P., Hellerbrand, C., Müller, T., Berg, T., Trautwein, C., Wasmuth, H.E. Genetic variations of the chemokine scavenger receptor D6 are associated with liver inflammation in chronic hepatitis C. **Hum Immunol**. 2008; 69(12):861-6. **IF 2.298**

Berres, M.L., Papen, S., Pauels, K., Schmitz, P., Zaldivar, M.M., Hellerbrand, C., Mueller, T., Berg, T., Weiskirchen, R., Trautwein, C., Wasmuth, H.E. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. **J Hepatol**. 2009; 50(2):370-6. **IF 10.401**

Wasmuth, H.E., Lammert, F., Zaldivar, M. M., Weiskirchen, R., Hellerbrand, C., Scholten, D., **Berres, M.L.**, Zimmermann, H., Streetz, K.L., Tacke, F., Hillebrandt, S., Schmitz, P., Keppeler, H., Berg, T., Dahl, E., Gassler, N., Friedman, S.L., Trautwein, C. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. **Gastroenterology**. 2009; 137(1):309-19, 319.e1-3. **IF 12.821**

Berres, M.L., Trautwein, C., Zaldivar, M.M., Schmitz, P., Pauels, K., Lira, S.A., Tacke, F., Wasmuth, H.E. The chemokine scavenging receptor D6 limits acute toxic liver injury in vivo. **Biol Chem**. 2009; 390(10):1039-45. **IF 2.683**

Zaldivar, M.M., Pauels, K., von Hundelshausen, P., **Berres, M.L.**, Schmitz, P., Bornemann, J., Kowalska, M.A., Gassler, N., Streetz, K.L., Weiskirchen, R., Trautwein, C., Weber, C., Wasmuth, H.E. CXC chemokine ligand 4 (CXCL4) is a platelet-derived mediator of experimental liver fibrosis. **Hepatology**. 2009; 51(4):1345-53. **IF 12.003**

Berres, M.L., Koenen, R.R., Rueland, A., Zaldivar, M.M., Heinrichs, D., Sahin, H., Schmitz, P., Streetz, K.L., Berg, T., Gassler, N., Weiskirchen, R., Proudfoot, A., Weber, C., Trautwein, C., Wasmuth, H.E. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. **J Clin Invest.** 2010;120(11):4129-40. **IF 12.812**

Berres, M.L., Lettow, I., Schmitz, P., Müller, T., Berg, T., Neumann, U.P., Trautwein, C., Wasmuth, H.E. A Duffy antigen receptor for chemokines (DARC) polymorphism that determines pro-fibrotic chemokine serum concentrations is not directly associated with severity of hepatitis C infection. **Hum Immunol.** 2011;72(3):273-7. **IF 2.298**

Berres, M.L., Trautwein, C., Schmeding, M., Eurich, D., Tacke, F., Bahra, M., Neuhaus, P., Neumann, U.P., Wasmuth, H.E. Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection. **Hepatology** 2011;53(2):596-603. **IF 12.003**

Tacke, F., Zimmermann, H.W., **Berres, M.L.**, Trautwein, C., Wasmuth, H.E. Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases. **Liver int.** 2011;31(6):840-9. **IF 3.870**

Berres, M.L., Schlosser, B., Berg, T., Trautwein, C., Wasmuth, H.E. Soluble Urokinase Plasminogen Activator Receptor is associated with progressive liver fibrosis in Hepatitis C infection. **J Clin Gastroenterol.** 2011. **IF 3.203**

Heinrichs, D., Knauel, M., Offermanns, C., **Berres, M.L.**, Nellen, A., Leng, L., Schmitz, P., Bucala, R., Trautwein, C., Weber, C., Bernhagen, J., Wasmuth, H.E. Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. **Proc Natl Acad Sci USA.** 2011, Oct 18;108(42):17444-9. **IF 9.737**

Moreno Zaldivar, M., **Berres, M.L.**, Sahin, H., Nellen, A., Heinrichs, D., Schmitz, P., Gassler, N., Streetz, K., Trautwein, C., Wasmuth, H.E. The chemokine receptor CXCR3 limits injury after acute toxic liver damage. **Lab Invest.** 2012 May;92(5):724-34. **IF 3.961**

Sahin, H., Borkham-Kamphorst, E., Kuppe, C., Zaldivar, M.M., Grouls, C., Al-Samman, M., Nellen, A., Schmitz, P., Heinrichs, D., **Berres, M.L.**, Doleschel, D., Scholten, D., Weiskirchen, R., Moeller, M.J., Kiessling, F., Trautwein, C., Wasmuth H.E. The chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice. **Hepatology.** 2012 May;55(5):1610-9. **IF 12.003**

Nellen, A., Heinrichs, D., **Berres, M.L.**, Sahin, H., Schmitz, P., Proudfoot, A.E., Trautwein, C., Wasmuth, H.E. Interference with oligomerization and glycosaminoglycan binding of the chemokine ccl5 improves experimental liver injury. **PLoS One** 2012;7(5):e36614. **IF 3.730**

Sahin, H., Borkham-Kamphorst, E., Cabral do O, Nicole., **Berres, M.L.**, Kaldenbach, M., Fischer, P., Weiskirchen, R., Liedtke, C., Streetz, K., Maedler, K., Trautwein, C., Wasmuth, H.E. Pro-apoptotic effects of the chemokine Cxcl10 are mediated by the

non-cognate receptor TLR4 in hepatocytes. **Hepatology**. 2012 May;55(5):1610-9. **IF 12.003**

Stock, M.K., Hammerich, L., do O, N.T., **Berres, M.L.**, Alsamman, M., Heinrichs, D., Nellen, A., Trautwein, C., Tacke, F., Wasmuth, H.E., Sahin, H. Met-CCL5 modifies monocyte subpopulations during liver fibrosis regression. **Int J Clin Exp Pathol**. 2013;6(4):678-85. **IF 2.242**

Heinrichs, D., **Berres, M.L.**, Nelle, A., Fischer, P., Scholten, D., Trautwein, C., Wasmuth, H.E., Sahin, H. The Chemokine CCL3 Promotes Experimental Liver Fibrosis in Mice. **PLoS One**. 2013 Jun 17;8(6):e66106. **IF 3.730**

Berres, M.L., Phaik-Har Lim, K., Peters, T., Price, J., Takizawa, H., Philip J. Lupo, P.J., Hicks, M.J., Shih, A., Simko, S.J., Heym, K.M., Bigley, V., Collin, M., Manz, M.G., McClain, K., Merad, M., Allen, C.E. BRAF-V600E Expression in Precursor Versus Mature Dendritic Cells Defines Clinically Distinct LCH Risk-Groups. **J Exp Med**. 2014 Apr 7;211(4):669-83. **IF 13.214**

Muller, P.A., Koscsó, B., Rajani, G., Stevanovic, K., **Berres, M.L.**, Hashimoto, D., Mortha, A., Leboeuf, M, Li, X, Stanley, E.R., Dahan, S., Gross Margolis, K., Gershon, M.D., Merad, M., Bogunovic, M. Crosstalk between Muscularis Macrophages and Enteric Neurons Regulates Gastrointestinal Motility. **Cell**. 2014 Jul 17;158(2):300-13. **IF 31.957**

Heinrichs, D., **Berres, M.L.**, Coeuru, M., Knauel, M., Nellen, A., Fischer, P., Phillippeit, C., Bucala, R., Trautwein, C., Wasmuth, H.E., Bernhagen, J. Protective role of macrophage migration inhibitory factor in non-alcoholic steatohepatitis. **FASEB J**. 2014 Aug; 14-256776, **IF 5.704**

Chakraborty, R., Hampton, O.A., Shen, X., Simko, S., Shih, A., Abhyankar, H., Lim, K.P., Covington, K., Trevino, L., Dewal, N., Muzny, D.M., Doddapaneni, H., Hu, J., Wang, L., Lupo, P.J., Hicks, M.J., Bonilla, D.L., Dwyer, K.C., **Berres, M.L.**, Poulidakos, P.I., Merad, M., McClain, K.L., Wheeler, D.A., Allen, C.E., Parsons, D.W. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. **Blood** 2014 Sep 8; 2014-05-577825, **IF 9.775**

Berres, M.L., Asmacher, S., Lehmann, J., Jansen, C., Strunk, H.M., Fimmers, R., Tacke, F., Strassburg, C.P., Trautwein, C., Sauerbruch, T., Wasmuth, H.E., Trebicka, J. Circulating CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt, **J Hepatol**. 2015 Feb;62(2):332-9.**IF 10.401**

Berres, M.L. Lehmann. J., Jansen, C., Görtzen, J., Meyer, C., Thomas, D., Strassburg, C., Sauerbruch, T., Trautwein, C., Wasmuth, H.E., Trebicka, J. CXCL11 levels predict survival in cirrhotic patients with TIPS, *Liver Int*. 2015 Jul 25; liv.12922. **IF 3.870**

Reviews:

Berres, M.L., Nellen, A., Wasmuth, H.E. Chemokines as immune mediators of liver diseases related to the metabolic syndrome, **Dig Dis**. 2010;28(1):192-6, **IF 2.725**

Sahin, H., **Berres, M.L.**, Wasmuth, H.E. Therapeutic potential of chemokine receptor antagonists for liver disease. **Expert Rev Clin Pharmacol**. 2011 Jul;4(4):503-13.

Berres, M.L., Allen, C.E., Merad, M. Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases. **Adv Immunol**. 2013;120:127-61. **IF 7.256**

Berres, M.L., Allen, C.E., Merad, M. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?. **Br J Haematol**. 2015 Apr;169(1):3-13. **IF 4.959**

Book chapters:

Berres, M.L., Moreno Zaldivar, M., Trautwein, C., and Wasmuth, H.E. Fibrosis regression and innovative antifibrotic therapies: from bench to bedside.

In: Sauerbruch (Hsg). Liver cirrhosis: from pathophysiology to clinics. Springer, Dordrecht 2008